Manufacturer
DUOPHARMA MANUFACTURING (BANGI) SDN BHD
Contents
Ranitidine HCl
Indication
NSAID-associated ulceration, Dyspepsia, Gastro-oesophageal reflux disease, Duodenal ulcers associated with H. pylori infection, Prophylaxis of gastrointestinal haemorrhage from stress ulceration, Prophylaxis of acid aspiration during general anaesthesia, Benign gastric and duodenal ulceration, Hypersecretory conditions.
Instruction
May be taken with or without food.
Drug interaction
Altered prothrombin time and increased serum concentration with coumarin anticoagulants (e.g. warfarin). May reduce the excretion and increase plasma concentrations of procainamide and N-acetylprocainamide (high dose ranitidine). May alter the absorption of pH-dependent drugs which may result in either an increase in absorption (e.g. triazolam, glipizide, midazolam) or decrease in absorption (e.g. atazanavir, gefitnib, ketoconazole, delaviridine). Decreased absorption with co-administration of high dose sucralfate.
Malaysia
